Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all malignancies, with a 5-year survival rate <8%.1,2 Suspicious lesions are typically diagnosed via endoscopic ultrasound-guided fine-needle aspiration or endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB).3 Fewer needle passes decreases the risk of postprocedure complications, including pancreatitis and hemorrhage, while allowing additional needle passes to be used for adjuvant tissue testing, such as organoid creation and DNA sequencing.

中文翻译：

---

单通道与 2 通道内窥镜超声引导下细针活检样本采集，用于创建胰腺癌类器官。

胰腺导管腺癌 (PDAC) 是所有恶性肿瘤中预后最差的一种，5 年生存率 <8%。1,2 可疑病变通常通过超声内镜引导的细针穿刺或超声内镜引导的细针穿刺来诊断- 针刺活检 (EUS-FNB)。3 更少的穿刺针减少了术后并发症的风险，包括胰腺炎和出血，同时允许额外的穿刺针用于辅助组织检测，例如类器官的创建和 DNA 测序。